**Trader consensus heavily favors "No" at 85% for a new COVID variant of concern before 2027, reflecting the absence of any Variants of Concern (VOCs) under current WHO and ECDC classifications as of mid-2026.** Global genomic surveillance shows SARS-CoV-2 continuing to evolve through Omicron sublineages such as XFG, NB.1.8.1, and BA.3.2, which have circulated at notable levels in parts of Europe and the U.S. without triggering VOC status. These strains are tracked only as variants under monitoring or interest, with data indicating no meaningful increases in transmissibility, severity, or immune escape beyond what existing immunity and updated 2025-2026 vaccines address. The high bar for VOC designation—requiring substantial public health impact—has not been met since earlier Omicron waves, and recent patterns point to incremental drift rather than sudden shifts. Market pricing aligns with this steady-state surveillance picture, where unexpected escalations remain possible but lack supporting signals in the latest sequencing and epidemiological reports.